AR017021A1 - Acido 2-hidroxiacetico - Google Patents

Acido 2-hidroxiacetico

Info

Publication number
AR017021A1
AR017021A1 ARP980104219A ARP980104219A AR017021A1 AR 017021 A1 AR017021 A1 AR 017021A1 AR P980104219 A ARP980104219 A AR P980104219A AR P980104219 A ARP980104219 A AR P980104219A AR 017021 A1 AR017021 A1 AR 017021A1
Authority
AR
Argentina
Prior art keywords
diseases
difluorocyclopentyl
salts
useful
compound
Prior art date
Application number
ARP980104219A
Other languages
English (en)
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of AR017021A1 publication Critical patent/AR017021A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere al ácido 2-hidroxiacético de formula general (III), donde Ar es fenilo, y R10 representa 3,3-difluorociclopentilo y sus sales. Enparticular la invencion se refiere al ácido (2R)-2-[(1R)-3,3-difluorociclopentil]-2-hidroxi-2-fenilacético y sus sales. El compuesto de la invencion esutil como reactivo para preparar derivados de piperidina 1,4-disustituida que contiene fluor. Los derivados preparados a partir del compuesto de lainvencion tienen no solo un antagonismo potente y selectivo para los receptores M3 muscarínicos sino también tienen pocos efectos colaterales. Más aun,exhiben una excelente actividad oral, duracion de accion y farmacocinética. Por lo tanto son utiles para el tratamiento y profilaxis de las enfermedadesrespiratorios, las enfermedades urinarias y las enfermedades digestivas.
ARP980104219A 1996-08-01 1998-08-25 Acido 2-hidroxiacetico AR017021A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21

Publications (1)

Publication Number Publication Date
AR017021A1 true AR017021A1 (es) 2001-08-22

Family

ID=26394715

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
ARP980104219A AR017021A1 (es) 1996-08-01 1998-08-25 Acido 2-hidroxiacetico
ARP980104218A AR016877A2 (es) 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980104218A AR016877A2 (es) 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales

Country Status (29)

Country Link
US (2) US5948792A (es)
EP (1) EP0930298B1 (es)
JP (1) JP3063164B2 (es)
KR (1) KR20000022214A (es)
CN (1) CN1226888A (es)
AR (3) AR008272A1 (es)
AT (1) ATE229941T1 (es)
AU (1) AU716050B2 (es)
BG (1) BG103114A (es)
BR (1) BR9711108A (es)
CA (1) CA2261680C (es)
CO (1) CO4960641A1 (es)
CZ (1) CZ33199A3 (es)
DE (1) DE69718026T2 (es)
EE (1) EE9900038A (es)
ES (1) ES2188961T3 (es)
HR (1) HRP970426A2 (es)
HU (1) HUP9902381A3 (es)
ID (1) ID17259A (es)
IL (1) IL127685A0 (es)
IS (1) IS4960A (es)
NO (1) NO990472D0 (es)
NZ (1) NZ333842A (es)
PE (1) PE92198A1 (es)
PL (1) PL331431A1 (es)
SK (1) SK12299A3 (es)
TR (2) TR200001482T2 (es)
WO (1) WO1998005641A1 (es)
YU (1) YU1299A (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
AU4194500A (en) 1999-04-08 2000-11-14 Banyu Pharmaceutical Co., Ltd. Diastereoselective preparation of michael adducts
AU4314700A (en) * 1999-04-28 2000-11-17 Banyu Pharmaceutical Co., Ltd. Processes for the preparation of piperidylmethylpyridine derivatives
WO2001013918A1 (en) * 1999-08-23 2001-03-01 H. Lundbeck A/S Treatment of urinary incontinence
US7238709B2 (en) 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
AU2001271027B2 (en) * 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
ATE305468T1 (de) 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
MXPA04002496A (es) * 2001-09-27 2004-05-31 Pharmacia Ab Composicion farmaceutica para el tratamiento de enfermedades urinarias.
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
NZ537584A (en) * 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
DE60226906D1 (de) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体
EP1562599A1 (en) * 2002-10-29 2005-08-17 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds as muscarinic receptor antagonists
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
ATE400553T1 (de) * 2002-12-10 2008-07-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009059B1 (ru) 2003-04-10 2007-10-26 Рэнбакси Лабораториз Лимитед Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
EP1615887A1 (en) * 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) * 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Msd株式会社 新規2−ヘテロアリール置換ベンズイミダゾール誘導体
US20080319002A1 (en) * 2004-06-16 2008-12-25 Ranbaxy Laboratories Limited Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
US20080280883A1 (en) * 2004-09-24 2008-11-13 Mohammad Salman Muscarinic Receptor Antagonists
EP1797040A1 (en) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7932394B2 (en) 2004-11-02 2011-04-26 Msd K.K. Aryloxy-substituted benzimidazole derivatives
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
EP1828126A1 (en) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
EP1935890B1 (en) * 2005-09-30 2016-03-16 Msd K.K. 2-heteroaryl-substituted indole derivative
US20090131410A1 (en) * 2005-10-05 2009-05-21 Naresh Kumar 3-azabicyclooctane derivatives as muscarinic receptor antagonists
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
CN101796026B (zh) * 2007-09-07 2013-10-23 施万制药 可用作毒蕈碱受体拮抗剂的含胍化合物
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives

Also Published As

Publication number Publication date
EE9900038A (et) 1999-08-16
AR008272A1 (es) 1999-12-29
AR016877A2 (es) 2001-08-01
EP0930298A1 (en) 1999-07-21
CZ33199A3 (cs) 1999-07-14
TR200001482T2 (tr) 2000-11-21
CA2261680A1 (en) 1998-02-12
EP0930298A4 (en) 2000-06-07
HRP970426A2 (en) 1998-08-31
BR9711108A (pt) 1999-08-17
TR199900204T2 (xx) 2000-01-21
PL331431A1 (en) 1999-07-19
DE69718026T2 (de) 2003-07-10
AU716050B2 (en) 2000-02-17
NO990472L (no) 1999-02-01
WO1998005641A1 (fr) 1998-02-12
ID17259A (id) 1997-12-11
PE92198A1 (es) 1999-01-09
ATE229941T1 (de) 2003-01-15
CO4960641A1 (es) 2000-09-25
IS4960A (is) 1999-01-29
ES2188961T3 (es) 2003-07-01
HUP9902381A3 (en) 2000-06-28
US6040449A (en) 2000-03-21
US5948792A (en) 1999-09-07
EP0930298B1 (en) 2002-12-18
SK12299A3 (en) 2000-05-16
NO990472D0 (no) 1999-02-01
DE69718026D1 (de) 2003-01-30
JP3063164B2 (ja) 2000-07-12
HUP9902381A2 (hu) 1999-11-29
NZ333842A (en) 2001-05-25
YU1299A (sh) 2002-03-18
CN1226888A (zh) 1999-08-25
AU3635197A (en) 1998-02-25
CA2261680C (en) 2005-03-08
IL127685A0 (en) 1999-10-28
BG103114A (en) 1999-11-30
KR20000022214A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
AR017021A1 (es) Acido 2-hidroxiacetico
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
UY26872A1 (es) Derivados de la 4- fenil piridina
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
CY1106784T1 (el) Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar)
PA8591701A1 (es) Derivados de pirrolopirimidina
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
BR0016747A (pt) Bases de mannich de indol substituìdas
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
UY26098A1 (es) Proceso para preparar derivados de ácidos ariloxiarilsulfonilamino hidroxamicos
EA200100841A1 (ru) Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
MEP41408A (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
UY27786A1 (es) Derivados de isoquinolina.
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.